市場調查報告書
商品編碼
1086976

腦脊液 (CSF) 管理的全球市場預測 (2022-2027)

Cerebrospinal Fluid (CSF) Management Market - Forecasts from 2022 to 2027

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 136 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球腦脊液 (CSF) 管理市場將從 2020 年的 75,373,000 美元增長到 2027 年的 961,845,000 美元,預測期內的複合年增長率為 4.53%,增長預期。

由於新興國家的多種神經治療設施的發展以及更便宜的治療機會的增加,市場正在擴大。神經系統疾病患病率的增加、微創手術的高需求、人口老齡化的增加、可支配收入的增加、醫療基礎設施的進步、先進設備的發展等是促成腦脊液管理設備市場增長的因素。 .

本報告對全球腦脊液 (CSF) 管理市場進行調查,包括市場概況、市場驅動因素和製約因素、產品類型/最終用戶/行業/區域分析、競爭格局、公司概況等。

目錄

第一章介紹

  • 市場定義
  • 市場細分

第二章調查方法

  • 調查數據
  • 先決條件

第 3 章執行摘要

  • 調查重點

第四章市場動態

  • 市場促進因素
  • 市場製約因素
  • 波特五力分析
    • 供應商議價能力
    • 買方的議價能力
    • 替代威脅
    • 新進入者的威脅
    • 行業競爭形勢
  • 產業價值鏈分析

第 5 章全球腦脊液 (CSF) 管理市場:按產品類型

  • 簡介
  • 腦脊液分流
  • 體外引流系統

第 6 章全球腦脊液 (CSF) 管理市場:按最終用戶

  • 簡介
  • 兒童
  • 成人
  • 老人

第 7 章全球腦脊液 (CSF) 管理市場:按行業

  • 簡介
  • 醫院
  • 診所
  • 其他

第 8 章全球腦脊液 (CSF) 管理市場:按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 其他
  • 中東/非洲
    • 沙特阿拉伯
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 印度尼西亞
    • 泰國
    • 台灣
    • 其他

第九章競爭環境與分析

  • 主要公司及戰略分析
  • 初創企業和市場優勢
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第 10 章公司簡介

  • Medtronic
  • Integra
  • DePuy Synthes
  • B.Braun
  • Spiegelberg GmbH & Co. KG
  • Sophysa (A subsidiary of tkb group)
  • Natus Medical Incorporated
  • Argi Grup
  • Moller Medical GMBH
  • Delta Surgical
  • Wellong Instruments Co., Ltd.
目錄
Product Code: KSI061611877

The global cerebrospinal fluid (CSF) management market is projected to grow at a CAGR of 4.53% during the forecast period to reach US$961.845 million by 2027, from US$705.373 million in 2020. Cerebrospinal fluid is a bodily fuel found in the brain and spinal cord that protects the brain mechanically and immunologically. Various management devices, such as CSF drainage systems and CSF shunts, are used to control the flow of CSF away from the ventricles in the body, preventing inappropriate CSF accumulation and hydrocephalus.

The expansion of the market is being aided by the development of several neuro hospitals in emerging countries, as well as increased chances for cheap treatment. The growing prevalence of neurological disorders, the high demand for minimally invasive surgeries, the growing geriatric population, rising disposable incomes, the advancement of healthcare infrastructure, and the development of advanced devices are among the contributing factors to the growth of the cerebrospinal fluid management devices market. Furthermore, the treatment of the disease demands advanced technology and infrastructure, both of which are commonly found in hospitals. Hospitals are treating various neurovascular illnesses as a result of the introduction of new products and technical improvements, that will give lucrative market growth prospects throughout the projected period. According to the National Institute of Neurological Disorders and Stroke, one to two out of every 1000 babies worldwide are born with hydrocephalus. . As a result, the prevalence of hydrocephalus is expected to rise in the future, given the total number of babies each year.

One of the most significant constraints on global business is the scarcity of qualified neurosurgeons. Globally, there is a major scarcity of qualified specialists. The existing number of neurosurgeons is insufficient to meet the demand for quality healthcare in a rapidly rising senior population. Rising problems connected with CSF shunts and sensor-related infections are two major issues that are predicted to limit the worldwide cerebrospinal fluid management market's growth in the projected period. Apart from that, the market's growth is hampered by the high cost of devices and the infections generated by CSF shunts.

Key Developments

CereVasc closed its Series A round of USD 43.9 million in June 2020, led by Perceptive Xontogeny Venture Fund and ATON Partners, focusing on the E-shunt system's clinical study as well as follow-up clinical research to support regulatory approvals. Biocept announced the commercial launch of the CNSide cerebrospinal fluid assay in April 2021 to meet the needs of patients with advanced brain cancer. Anuncia announced that its ReFlow system for CSF management obtained FDA breakthrough device designation in March 2020.

By product type, the global cerebrospinal fluid (CSF) management market can be segmented into external drainage systems and shunts. Shunts are expected to dominate the cerebrospinal fluid (CSF) management industry in the next few years owing to the rising number of shunting procedures conducted worldwide, as well as the increasing number of revision shunt surgeries due to shunt malfunction and infection, which can be linked to this product segment's substantial market share. The advantages associated with these shunts over traditional shunts, such as the reduced likelihood of revision surgery and a shorter average length of hospital stay, are fuelling the expansion of this market.

By end-users, the global cerebrospinal fluid (CSF) management market can be segmented into adult, pediatric, and geriatric. During the forecast period, the pediatric category is estimated to account for a considerable revenue share in the market. The increased prevalence of congenital hydrocephalus and the increasing number of shunting procedures performed in the pediatric population are responsible for the high revenue growth. Furthermore, the geriatric segment is anticipated to have significant market growth due to the rising burden of neurological disorders and an aging population.

By industry, the global cerebrospinal fluid (CSF) management market can be segmented into hospitals, clinics, and others. Due to a large number of hospital cases linked to CSF management in the aging population, the hospital segment is anticipated to account for a sizable market share and is expected to expand at the fastest rate over the projection period.

By geography, the global cerebrospinal fluid (CSF) management market can be segmented into the Asia Pacific, North America, the Middle East and Africa, South America, and Europe. Over the projected period, the Asia Pacific region is expected to grow at the highest rate. The developing medical tourism in India and other Asia Pacific countries, the rising prevalence of congenital hydrocephalus in China, and the growing geriatric population in various nations in the area are all factors driving revenue growth in this regional market.

Covid-19 Insights

The COVID-19 epidemic impacted the global cerebrospinal fluid (CSF) management market significantly. The COVID-19 epidemic wreaked havoc on the hospital system by forcing the admission of large numbers of critically ill patients. COVID-19 treatment became a priority as a result of this delay in other healthcare deliveries. In addition, the installation of lockdowns hampered research and awareness programs. However, since the viral outbreak, the situation has greatly improved. With global recognition of the importance of R&D in healthcare and the development of breakthrough products, the healthcare industry has seen a surge in investment. As a result of increased investment activity, the CSF management industry is likely to grow rapidly.

Market Segmentation:

  • By Product Type

CSF Shunts

External Drainage Systems

  • By End-Users

Pediatric

Adult

Geriatric

  • By Industry

Hospitals

Clinics

Others

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Powers of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. Threat of New Entrants
    • 4.3.5. Competitive Rivalry in Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL CEREBROSPINAL FLUID (CSF) MANAGEMENT MARKET, BY PRODUCT TYPE 

  • 5.1. Introduction
  • 5.2. CSF Shunts
  • 5.3. External Drainage Systems

6. GLOBAL CEREBROSPINAL FLUID (CSF) MANAGEMENT MARKET, BY END-USERS 

  • 6.1. Introduction
  • 6.2. Pediatric
  • 6.3. Adult
  • 6.4. Geriatric

7. GLOBAL CEREBROSPINAL FLUID (CSF) MANAGEMENT MARKET, BY INDUSTRY

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Others

8. GLOBAL CEREBROSPINAL FLUID (CSF) MANAGEMENT MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom 
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. Israel
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Taiwan 
    • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisition, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES 

  • 10.1. Medtronic
  • 10.2. Integra 
  • 10.3. DePuy Synthes
  • 10.4. B.Braun
  • 10.5. Spiegelberg GmbH & Co. KG
  • 10.6. Sophysa (A subsidiary of tkb group), 
  • 10.7. Natus Medical Incorporated, 
  • 10.8. Argi Grup
  • 10.9. Moller Medical GMBH 
  • 10.10. Delta Surgical
  • 10.11. Wellong Instruments Co., Ltd.